Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

4SC commences dosing in a first-in-man phase I study of 4SC-203

Jan. 22, 2010

Sorafenib shows low activity in phase II trial in advanced biliary tract carcinoma

Jan. 22, 2010

Synta Pharmaceuticals discloses Hsp90 inhibitors for the treatment of cancer

Jan. 22, 2010

Everolimus effective in patients with metastatic pancreatic neuroendocrine tumors

Jan. 22, 2010

Banyu and Merck & Co. claim novel Akt1 inhibitors for cancer therapy

Jan. 22, 2010

Phase II data show ixabepilone to be safe and efficacious in ovarian cancer

Jan. 21, 2010

Spear Therapeutics discloses novel compounds for cancer treatment

Jan. 21, 2010

Sunitinib activity limited in patients with squamous cell carcinoma of the head and neck

Jan. 21, 2010

EMEA Pediatric Committee grants product-specific waivers for StemEx

Jan. 21, 2010

GenVec reports key event in phase III trial of TNFerade in advanced pancreatic cancer

Jan. 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.